title: Anti-tumor necrosis factor-α induced systemic lupus erythematosus in a patient with metastatic Crohn's disease--what is the role of anti-TNF antibody?
abstract: Biological therapies are supposed to trigger the development of autoimmune diseases. We report a case of a 27-year old woman presenting with drug induced systemic lupus erythematosus (SLE) associated with infliximab therapy. The development of paradoxical inflammation in immune-mediated inflammatory diseases patients treated with anti TNF-α suggests that an unknown inflammatory pathway may be provoked by inhibiting TNF-α. We suppose that in our case a cross reactivity between anti-infliximab antibodies and autoantibodies may lead to the development of TNF-induced immune disease.
authors: First Department of Medicine, University of Szeged, Szeged, Hungary.
authors: Klaudia
authors: K
authors: Farkas
authors: Ferenc
authors: F
authors: Nagy
authors: László
authors: L
authors: Kovács
authors: Tibor
authors: T
authors: Wittmann
authors: Tamás
authors: T
authors: Molnár
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000069285:Infliximab; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced* / Q000150:complications / Q000175:diagnosis / Q000276:immunology
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D000069285:Infliximab